In an attempt to better understand the mechanisms by which rosiglitazone acts improving EPC function, Zhou et al. found that the 4-weeks rosiglitazone treatment of a T2DM murine model enhanced the in vivo wound healing and angiogenesis via stimulation of VEGF and SDF-1 [175]. The gene discussed is CXCL12; the disease is type 2 diabetes mellitus.